Picture of Prestige Consumer Healthcare logo

PBH — Prestige Consumer Healthcare News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapSuper Stock

Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook

Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook


Overview

  • US consumer healthcare firm's fiscal Q1 revenue rose 6.5%, beating analyst expectations

  • Adjusted diluted EPS for fiscal Q1 rose to $0.98 from $0.95 last year

  • Company closed Breathe Right and LaCorium acquisitions, raising fiscal 2027 outlook


Outlook

  • Company raises fiscal 2027 revenue outlook to $1.29 bln-$1.315 bln including acquisitions

  • Prestige Consumer Healthcare expects fiscal 2027 adjusted diluted EPS of $4.55-$4.65

  • Company projects fiscal 2027 adjusted free cash flow of $270 mln or more


Result Drivers

  • CATEGORY STRENGTH - Organic growth in Gastrointestinal and Dermatological categories contributed to Q1 revenue gains

  • ACQUISITION IMPACT - Breathe Right acquisition added $6 mln to Q1 revenue

  • WORKING CAPITAL - Higher adjusted free cash flow was due to the timing of working capital


Company press release: ID:nGNX18QPtM


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

Beat

$265.71 mln

$250.33 mln (7 Analysts)

Q1 Net Income

$29.18 mln

Q1 Gross Profit

$136.19 mln

Q1 Operating Expenses

$83.67 mln

Q1 Operating Income

$52.52 mln

Q1 Pretax Profit

$38.54 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc is $69.50, about 31.2% above its August 5 closing price of $52.98

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Aug 5 - Edgewell Personal Care Q3 sales miss estimates; narrows FY outlook

  • Aug 5 - Ireland's Perrigo Q2 profit beats on portfolio streamlining

  • Aug 4 - P&G buys supplements maker Thorne for $3.8 billion as wellness push intensifies


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Prestige Consumer Healthcare

See all news